Respiratory News and Research

RSS

Public restrooms could serve as hotbeds for COVID-19 transmission

Flushing a toilet can generate large quantities of microbe-containing aerosols depending on the design, water pressure or flushing power of the toilet. A variety of pathogens are usually found in stagnant water as well as in urine, feces and vomit.

20 Apr 2021

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Opioid addicts wage a daily war within over whether or not to use a drug whose side effect can be death. If those same addicts, however, had the choice to take an opioid vaccine once or twice a year, their internal struggle could be over.

20 Apr 2021

Study offers new insights on sleep apnea surgery, postoperative respiratory depression

An estimated 50 million people undergo surgery each year in the United States, and a significant proportion of them have undiagnosed or untreated sleep disorders (SD) or sleep-disordered breathing (SDB).

20 Apr 2021

Use of ozone as a decontaminant for SARS-CoV-2

Researchers in Germany have demonstrated how an ozone-based decontamination device significantly reduces the volume of viral residue left on surfaces of two surrogate viruses for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

20 Apr 2021

Screening drug candidates for COVID-19 treatment using computational methods

Researchers identified two potential drug candidates that can inhibit SARS-CoV-2 in vitro. Their combination can work synergistically and increase their inhibitory effect.

19 Apr 2021

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

CoronaVac is a well-tolerated vaccine containing inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and it induced humoral responses in phase 1 and 2 studies. Analysis of a Brazilian phase 3 clinical trial that evaluated 12,607 participants showed that the vaccine had an efficacy of 50.39% 15 days after the 2nd dose.

19 Apr 2021

Study identifies COVID-19 vaccine inequity in Massachusetts

A new study led by Bisola O. Ojikutu of Brigham and Women’s Hospital in Boston suggests not only do these communities have a higher infection, but they are also experiencing lower vaccine distribution. The team suggests that reformation for equitable vaccine delivery is necessary to eliminate the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

COVID-19 patients who are overweight or obese may develop a more severe infection

COVID-19 patients who are overweight or obese are more likely to develop a more severe infection than patients of healthy weight, and they require oxygen and invasive mechanical ventilation more often. There is no increased risk of death .

19 Apr 2021

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

A small study, previously posted to the medRiv preprint server in early March, was recently published in the journal Science Immunology. The now peer-reviewed research led by E. John Wherry of the University of Pennsylvania Perelman School of Medicine finds people previously exposed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) produced a more robust immune response after receiving the first — but not the second mRNA vaccine.

19 Apr 2021

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers in the United States have demonstrated how to estimate the potentially waning efficacy of vaccines designed to protect against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

19 Apr 2021

Researchers manufacture the SARS-CoV-2 RBD in pichia

Researchers in the United States and India have developed a high-volume, low-cost platform for manufacturing vaccines to protect against different variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

19 Apr 2021

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

A recent scientific report from Israel shows how healthcare workers previously infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present with higher Immunoglobulin G (IgG) titers after receiving one dose of Pfizer–BioNTech COVID-19 vaccine in comparison to their fully vaccinated, never-infected counterparts. Conversely, the occurrence of post-vaccination infection does not increase IgG titers.

19 Apr 2021

Occurrence and persistence of SARS-CoV-2 in wastewater

Researchers review the utilities of wastewater epidemiology in assessing the prevalence of SARS-CoV-2 in a given community as well as the risks of wastewater viral transmission.

19 Apr 2021

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

A team of scientists in Germany recently evaluated the specificities and sensitivities of different serological assays for detecting antibodies against SARS-CoV-2.

19 Apr 2021

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Two researchers from the Université Libre de Bruxelles in Belgium, Fabrizio Pucci and Marianne Rooman, recently built a simplified computational model, called SpikePro, to predict the SARS-CoV-2 fitness from the amino acid sequence and structure of the spike protein. This study focuses on the spike protein’s stability and the binding affinity to the host receptor.

19 Apr 2021

Could a tuna-derived protein inhibit SARS-CoV-2?

A recent study in the journal Food Chemistry draws attention to the need for finding nutritional supplements with potential SARS-CoV-2 inhibition effects in the wake of the COVID-19 pandemic.

19 Apr 2021

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

The lack of new or repurposed drugs to treat patients with severe or critical COVID-19 has been one of the biggest hurdles to reducing mortality rates in the ongoing pandemic caused by SARS-CoV-2. A new study describes the potential for the use of the plant molecule isorhamnetin in the management of this virus.

19 Apr 2021

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

A new study, released as a preprint on the bioRxiv* server, casts some light on the pathogenesis of acute and subacute neurological complications associated with COVID-19.

19 Apr 2021

Study assess prevalence of SARS-CoV-2 in England after third national lockdown

In a new study, the REACT-1 research group offer their findings on the rate of SARS-CoV-2 infection in England after the country went into a third national lockdown. Their findings show a 60% reduction of incidence from their previous round of surveillance.

19 Apr 2021

Antibodies may not inhibit SARS-COV-2 variants from mink

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals.

19 Apr 2021

Respiratory News and Research

Public restrooms could serve as hotbeds for COVID-19 transmission

Scientists receive NIH grant to develop an adjuvant vaccine for opioid use disorder

Study offers new insights on sleep apnea surgery, postoperative respiratory depression

Use of ozone as a decontaminant for SARS-CoV-2

Screening drug candidates for COVID-19 treatment using computational methods

Sinovac COVID-19 vaccine shows 50% effectiveness in a cohort of Brazilian healthcare workers

Study identifies COVID-19 vaccine inequity in Massachusetts

COVID-19 patients who are overweight or obese may develop a more severe infection

Just one mRNA vaccine dose sufficient for people with prior SARS-CoV-2 infection

Researchers show how to evaluate waning efficacy of COVID-19 vaccines

Researchers manufacture the SARS-CoV-2 RBD in pichia

One dose of mRNA vaccine may be sufficient for individuals previously infected with SARS-CoV-2

Occurrence and persistence of SARS-CoV-2 in wastewater

Researchers reveal long-term kinetics of anti-SARS-CoV-2 antibodies in patient sera

Researchers develop computational model to predict changes in SARS-CoV-2’s viral fitness

Could a tuna-derived protein inhibit SARS-CoV-2?

Plant-derived compound isorhamnetin may have antiviral potential against SARS-CoV-2

SARS-CoV-2 nucleoprotein can trigger α-synuclein amyloid fibril formation

Study assess prevalence of SARS-CoV-2 in England after third national lockdown

Antibodies may not inhibit SARS-COV-2 variants from mink

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News